DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report
Stay informed about the cutting-edge advancements in B-Cell Non-Hodgkin Lymphoma Treatments. Download for updates and be a part of the revolution in care @ B-Cell Non-Hodgkin Lymphoma Clinical Trials Assessment
B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile
Valemetostat: Daiichi Sankyo
Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.
MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.
CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.
LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.
Learn more about B-Cell Non-Hodgkin Lymphoma Drugs opportunities in our groundbreaking B-Cell Non-Hodgkin Lymphoma Research and development projects @ B-Cell Non-Hodgkin Lymphoma Unmet Needs
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
Discover the latest advancements in B-Cell Non-Hodgkin Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives
Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Non-Hodgkin Lymphoma Pipeline on our website @ B-Cell Non-Hodgkin Lymphoma Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/